Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
Capricor Therapeutics has secured a July 29 FDA advisory committee meeting for deramiocel after a positive Phase 3 trial revived the previously rejected Duchenne muscular dystrophy application. The therapy now has controlled evidence of skeletal and cardiac benefit, but regulators must still weigh endpoint interpretation, long-term external comparisons, manufacturing reliability and whether the proposed label
PorTal Access can begin commercialising its FLEXI-PORT implantable vascular access system for adults and children. Its flexible design, chest-or-arm placement options and smaller implantation profile could improve long-term infusion access, but clinical adoption will depend on complication data, hospital economics and proof that design changes produce meaningful patient benefits.
Avacta Group PLC has agreed a potential full-approval pathway for faridoxorubicin with the United States Food and Drug Administration, while new clinical analyses suggest the drug may work even in tumours with very low FAP expression. The pivotal opportunity is becoming clearer, but Avacta still needs mature progression-free survival data, a development partner and evidence
Aidoc has secured FDA Breakthrough Device Designation for First Read, an investigational artificial intelligence system designed to analyse chest radiographs and generate preliminary report text. The technology could reduce reporting pressure, but automation bias, missed findings and unclear liability remain significant barriers.
The FDA has accepted Replimune’s latest RP1 resubmission and set an August 2 decision date, reviving a melanoma programme rejected twice over trial-design and efficacy questions. A late-July advisory committee will determine whether durable responses can outweigh the absence of definitive controlled evidence.
UpDoc is moving patient-facing artificial intelligence beyond reminders and administrative support into insulin management. Its narrow FDA clearance, physician-defined limits and early clinical evidence reveal both the potential and the boundaries of autonomous chronic-disease care.
CalciMedica has preserved the clinical future of Auxora after regulators reviewed safety data from the KOURAGE trial, but restarting development is only the beginning of a difficult scientific and financial recovery.
CONNEQT Health is seeking an FDA pathway for cloud-based arterial analytics, but regulatory execution, customer integration, cash burn and a heavily dilutive capital raise complicate the ASX micro-cap opportunity.
FDA clearance for contactless respiratory-rate measurement expands PanopticAI’s regulated digital-health platform, but restricted use, cloud dependence and uncertain reimbursement remain major commercial tests.